UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):August 12, 2016
Bionik Laboratories Corp. |
| (Exact Name of Registrant as Specified in Its Charter) |
| Delaware | | 000-54717 | | 27-1340346 |
| (State or Other Jurisdiction of Incorporation or Organization) | | (Commission File Number) | | (IRS Employer Identification No.) |
483 Bay Street, N105 Toronto, ON | | M5G 2C9 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (416) 640-7887
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 5.07 | Submission of Matters to a Vote of Security Holders |
The Annual Meeting of Stockholders (the “Annual Meeting”) of Bionik Laboratories Corp. (the “Company”) was held on August 12, 2016. At the Annual Meeting, the stockholders voted on the following four proposals and cast their votes as described below. The proposals are described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on July 12, 2016.
| Proposal 1: | Election of the five nominees listed below to serve on the Board of Directors of the Company until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: |
Nominee | | For | | Withhold Authority |
| Peter Bloch | | 59,163,159 | | 267,169 |
| Michal Prywata | | 59,162,459 | | 267,869 |
| Hermano Igo Krebs | | 59,135,540 | | 294,788 |
| Robert Hariri | | 59,162,459 | | 267,869 |
| Marc Mathieu | | 59,037,459 | | 392,869 |
| Proposal 2: | To approve an amendment to the Company’s certificate of incorporation to effect a reverse stock split of its issued and outstanding common stock. |
For | | Against | | Abstain |
| 59,968,816 | | 620,959 | | 197,448 |
| Proposal 3: | To amend the Company’s 2014 Equity Incentive Plan to change the number of shares of common stock authorized thereunder for grant from 10,800,000 to 15% of the shares of common stock and Exchangeable Shares issued and outstanding, and increase certain award limits. |
For | | Against | | Abstain |
| 48,210,145 | | 3,893,535 | | 7,326,648 |
| Proposal 4. | To ratify MNP, LLP as the Company’s independent public accountants for the year ending March 31, 2017. |
For | | Against | | Abstain |
| 59,147,687 | | 381,569 | | 262,500 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: August 17, 2016
| | BIONIK LABORATORIES CORP. | |
| | | | |
| | | | |
| | By: | /s/Leslie Markow | |
| | Name: | Leslie Markow | |
| | Title: | Chief Financial Officer | |
